Regeneron’s Linvoseltamab Study: A Potential Game-Changer for Multiple Myeloma Treatment

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals is conducting a Phase 1/2 study titled ‘Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma.’ The study aims to evaluate the safety and optimal dosing of linvoseltamab, a potential treatment for multiple myeloma, while also assessing its efficacy in combating cancer. The significance of this study lies in its potential to offer new therapeutic options for patients with relapsed or refractory multiple myeloma.

The intervention being tested is linvoseltamab, a bispecific antibody designed to target and treat multiple myeloma. The study explores different dosing regimens, including intravenous and subcutaneous administration, to determine the most effective approach.

The study follows an interventional design with a non-randomized, sequential intervention model. There is no masking involved, and the primary purpose is treatment. This straightforward design allows for a focused evaluation of linvoseltamab’s safety and efficacy.

The study began on November 29, 2018, with the latest update submitted on August 26, 2025. These dates are crucial as they mark the progression and ongoing nature of the study, indicating continued recruitment and data collection efforts.

The market implications of this study update could be significant for Regeneron Pharmaceuticals, potentially influencing stock performance and investor sentiment. As the study progresses, positive results could enhance Regeneron’s position in the competitive oncology market, especially against other companies developing treatments for multiple myeloma.

The study is currently recruiting, and further details are available on the ClinicalTrials portal.